STATEMENT: After Years Of Advocacy, Patients Will See Long-Awaited Relief From Eli Lilly’s Insulin Price Cut
“It’s Time For The Other Big Insulin Corporations To Follow Suit”
“It’s Time For The Other Big Insulin Corporations To Follow Suit”
Patient Advocate Lisa Ann Wetzel-Trainor Moderated A Conversation Where Merith Answered Questions On Her Background, The Inflation Reduction Act, And P4AD’s Future Goals:
The following statement was issued by David Mitchell, a cancer patient and founder and president of Patients For Affordable Drugs, in response to the pricing of Relyvrio following the Food and Drug Administration’s approval of the drug combination to treat amyotrophic lateral sclerosis (ALS):
Basey Has Devoted Her Career To Ensuring That Life-saving Medications Are Affordable And Accessible For All Who Need Them
In The Third Year Of The Pandemic And As Americans Grapple With Record Inflation, Big Pharma Continues To Raise Prices And Exploit Patients
A new report issued today documents how drug companies use their market and political power to avoid competition and raise prices in lockstep.
Since P4AD’s initial report in mid-January, drug companies have increased the price of 188 more drugs, bringing the total to 742 hikes so far this year.
The report demonstrates why urgent congressional action is needed to address Big Pharma’s abusive pricing practices.
Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.